

-124-

## I Claim:

1. A polypeptide capable of specifically activating cytotoxic T lymphocytes *in vivo*, wherein said cytotoxic T lymphocytes (CTLs) specifically target malignant cells.
2. The polypeptide of claim 1, wherein said polypeptide is derived from human p53 protein.
3. The polypeptide of claim 2, wherein said polypeptide has an amino acid residue sequence selected from the group consisting of:  
STPPPGTRV;  
LLGRNSFEV; and  
sequential subsets thereof.
4. The polypeptide of claim 1, wherein said polypeptide is derived from human Her-2/Neu protein.
5. The polypeptide of claim 4, wherein said polypeptide has an amino acid residue sequence selected from the group consisting of:  
KIFGSLAFL;  
VMAGVGSPYV; and  
sequential subsets thereof.
6. A polypeptide having substantial homology with a CTL epitope selected from the group consisting of:  
STPPPGTRV;  
LLGRNSFEV;  
KIFGSLAFL;  
VMAGVGSPYV; and  
sequential subsets thereof.
7. The polypeptide of claim 6, incorporated into a pharmaceutical composition further comprising a pharmaceutically acceptable carrier.
8. A population of specific cytotoxic T cells capable of lysing tumor cells displaying a specific peptide.
9. The population of claim 8, wherein said peptide is displayed exogenously.
10. The population of claim 8, wherein said peptide is displayed endogenously.
11. The population of claim 8, wherein said CTLs are generated via *in vivo* immunization.
12. The population of claim 8, wherein said specific peptide is derived from p53.

-125-

13. The population of claim 8, wherein said specific peptide is derived from Her-2/Neu.

14. A vaccine comprising an immunogenically effective amount of a cytotoxic T-lymphocyte-stimulating peptide.

15. The vaccine of claim 14, wherein said peptide is selected from the group consisting of:

STPPPGTRV;

LLGRNSFEV;

KIFGSLAFL;

VMAGVGSPYV; and

sequential subsets thereof.

16. The vaccine of claim 14, wherein said peptide is linked to a carrier.

17. The vaccine of claim 14, wherein said peptide is introduced into a mammal as a homopolymer.

18. The vaccine of claim 14, wherein said peptide is introduced into a mammal as a heteropolymer.

19. A method of generating activated CTL cells *in vivo*, which method comprises contacting, *in vivo*, CTL cells with antigen-loaded Class I molecules surface-expressed on murine cells for a time period sufficient to activate, in an antigen-specific manner, said CTL cells.

20. The method of claim 19, wherein said Class I molecules are human Class I MHC molecules.

21. The method of claim 19, wherein said Class I molecules are chimeric human-mouse Class I MHC molecules.

22. The method of claim 19, further comprising:

a. separating said activated CTL cells from said antigen-loaded Class I MHC molecules;

b. suspending said activated CTL cells in an acceptable carrier or excipient; and

c. administering said suspension to an individual in need of treatment.

23. A method of generating CTL cells that will target a specific population of cells, comprising:

a. administering an immunogenic polypeptide specific to said specific population of cells to an animal, thereby generating a population of antigen-loaded Class I molecules displaying said polypeptides on their cell surfaces;

b. contacting, *in vivo*, a population of CTL cells with said population of antigen-loaded Class I molecules for a time period sufficient to activate, in an

-126-

antigen-specific manner, said CTL cells; and

c. harvesting said activated CTL cells from said animal.

24. The method of claim 23, wherein said polypeptide is selected from the group consisting of:

LLPENNVLSPL;

RMPEAAPPV;

STPPPGTRV;

LLGRNSFEV;

and sequential subsets thereof.

25. The method of claim 23, wherein said polypeptide is selected from the group consisting of:

KIFGSLAFL;

VMAGVGSPYV; and

sequential subsets thereof.

26. The method of claim 23, wherein said Class I molecules are human Class I MHC molecules.

27. The method of claim 23, wherein said Class I molecules are chimeric human-mouse Class I MHC molecules.

28. A method of specifically killing target cells in an individual using specific, activated CTLs, comprising the following steps:

a. obtaining a fluid sample containing T cells from said individual;

b. loading empty Class I MHC molecules with at least one species of antigenic peptide, wherein the peptide is substantially homologous to at least a portion of a peptide derived from said target cell;

c. admixing said T cells with an amount of peptide-loaded Class I MHC molecules sufficient to produce activated CTLs;

d. harvesting said activated CTLs; and

e. administering said activated CTLs to said individual.

29. A method of provoking an immune response to a tumor-associated antigen, comprising contacting a cytotoxic T lymphocyte with an immune response-provoking amount of a molecule comprising a peptide selected from the group consisting of:

STPPPGTRV;

LLGRNSFEV;

KIFGSLAFL;

VMAGVGSPYV; and

sequential subsets thereof.

-127-

30. The method of claim 29, wherein said contacting occurs in a mammal.
31. The method of claim 29, wherein said contacting occurs *in vitro*.
32. The method of claim 29, wherein said method further comprises returning said contacted cytotoxic T cells to the host.
33. The method of claim 29, wherein said polypeptide is co-administered with a second polypeptide that induces a T helper response.
34. The method of claim 29, wherein said polypeptide and said T helper-inducing polypeptide are conjugated to one another.
35. A method of identifying specific cytotoxic T cells (CTLs) responsive to a specific T cell epitope, comprising the following steps:
- obtaining a test sample of lymphocytes from an individual, wherein said test sample is to be assayed for the presence of said specific CTLs;
  - contacting target cells with a molecule comprising a peptide selected from the group consisting of STPPPGTRV, LLGRNSFEV, KIFGSLAFL, VMAGVGSPYV, and sequential subsets thereof, wherein said target cells are of the same HLA class as said lymphocytes to be tested for said specific CTLs;
  - contacting said test sample with a molecule according to step b, under conditions sufficient to restimulate said specific CTLs to respond to appropriate target cells; and
  - determining whether said test sample of lymphocytes exerts a cytotoxic effect on said target cells, thereby confirming the presence of said specific CTLs.
36. A method of detecting specific cytotoxic T cells (CTLs) having receptors capable of binding a specific T cell epitope in a tissue sample, comprising the following steps:
- obtaining a test sample of lymphocytes from an individual, wherein said test sample is to be assayed for the presence of said specific CTLs;
  - contacting said test sample with a molecule comprising a label and a peptide selected from the group consisting of STPPPGTRV, LLGRNSFEV, KIFGSLAFL, VMAGVGSPYV, and sequential subsets thereof, to form an admixture;
  - maintaining said admixture under suitable assay conditions for a predetermined period of time, sufficient to restimulate any specific CTLs in said test sample to respond to appropriate target cells;
  - harvesting such contacted cells and washing with medium in the

-128-

absence of the labeled molecule sufficient to remove any unbound labeled molecule; and

e. measuring the bound labeled molecule using suitable measuring means.

5

37. A method of detecting anti-p53 antibodies in an individual, comprising:

a. obtaining a fluid sample from an individual to be tested;

b. adding a predetermined amount of p53 polypeptide to said sample, to form an admixture;

10

c. maintaining said admixture under biological assay conditions for a period of time sufficient to allow said p53 polypeptide to immunoreact with any anti-p53 antibodies present in said sample; and

d. assaying for the presence of an immunoreaction product, thereby confirming the presence of anti-p53 antibodies.

15

38. The method of claim 37, wherein said p53 polypeptide is selected from the group consisting of STPPPGTRV, LLGRNSFEV, KIFGSLAFL, VMAGVGSPYV, and sequential subsets thereof.

20

39. The method of claim 37, wherein said p53 polypeptide comprises two or more different polypeptides selected from the group consisting of STPPPGTRV, LLGRNSFEV, KIFGSLAFL, VMAGVGSPYV, and sequential subsets thereof.

25

40. An assay system in kit form comprising a package containing, in an amount sufficient to perform at least one assay, at least one species of polypeptide comprising no more than about 50 amino acid residues and including an amino acid residue sequence selected from the group consisting of:

LLPENNVLSPL;

RMPEAAPPV;

STPPPGTRV;

LLGRNSFEV; and

sequential subsets thereof.

30

41. The assay system according to claim 40, wherein said polypeptide is affixed to a solid matrix.

42. The assay system according to claim 40, wherein said polypeptide comprises more than one species of polypeptide and wherein said species are present as an admixture.

35

43. The assay system according to claim 40, further including, in a separate package, a labeled specific binding agent for signaling the presence of a polypeptide-containing immunoreaction product.

-129-

44. An assay system in kit form comprising a package containing, in an amount sufficient to perform at least one assay, an antibody combining site-containing molecule capable of immunoreacting with a tumor-associated antigen.

5 45. The assay system according to claim 40, wherein said molecule is affixed to a solid matrix.

46. The assay system according to claim 40, wherein said molecule is labeled.

47. An antibody molecule that immunoreacts with a polypeptide according to claim 1.

10 48. An antibody molecule according to claim 47, wherein said antibody molecule is monoclonal.

49. An antibody molecule according to claim 47, wherein said antibody molecule is polyclonal.

15 50. A composition comprising one or more antibody molecules according to claim 47.

51. A hybridoma capable of secreting an antibody according to claim 47.

52. A molecule comprising a polypeptide having substantial homology with a CTL epitope selected from the group consisting of:

20 STPPPGTRV;  
LLGRNSFEV;  
KIFGSLAFL;  
VMAGVGSPYV; and  
sequential subsets thereof.

25 53. The molecule of claim 52, wherein said molecule comprises at least about eight amino acids and fewer than about 50 amino acids.

54. The molecule of claim 52, wherein said molecule comprises at least about eight amino acids and fewer than about thirteen amino acids.

55. The molecule of claim 52, wherein said polypeptide has an amino acid residue sequence substantially homologous to that of any of said CTL epitopes.

30 56. The molecule of claim 52, wherein said polypeptide is conjugated to a substance, wherein said substance is selected from the group consisting of a radiolabel, an enzyme, a fluorescent label, a solid matrix, a carrier, and a second CTL epitope.

35 57. The molecule of claim 52, wherein said substance is a second CTL epitope.

58. The molecule of claim 52, wherein said second epitope is a T helper epitope.

60. The molecule of claim 52, wherein said polypeptide is conjugated to said substance indirectly by a linker.

1. **Introduction**  
 2. **Background**  
 3. **Methodology**  
 4. **Results**  
 5. **Discussion**  
 6. **Conclusion**  
 7. **References**  
 8. **Appendix**  
 9. **Index**  
 10. **Table of Contents**  
 11. **Figure 1**  
 12. **Figure 2**  
 13. **Figure 3**  
 14. **Figure 4**  
 15. **Figure 5**  
 16. **Figure 6**  
 17. **Figure 7**  
 18. **Figure 8**  
 19. **Figure 9**  
 20. **Figure 10**  
 21. **Figure 11**  
 22. **Figure 12**  
 23. **Figure 13**  
 24. **Figure 14**  
 25. **Figure 15**  
 26. **Figure 16**  
 27. **Figure 17**  
 28. **Figure 18**  
 29. **Figure 19**  
 30. **Figure 20**  
 31. **Figure 21**  
 32. **Figure 22**  
 33. **Figure 23**  
 34. **Figure 24**  
 35. **Figure 25**  
 36. **Figure 26**  
 37. **Figure 27**  
 38. **Figure 28**  
 39. **Figure 29**  
 40. **Figure 30**  
 41. **Figure 31**  
 42. **Figure 32**  
 43. **Figure 33**  
 44. **Figure 34**  
 45. **Figure 35**  
 46. **Figure 36**  
 47. **Figure 37**  
 48. **Figure 38**  
 49. **Figure 39**  
 50. **Figure 40**  
 51. **Figure 41**  
 52. **Figure 42**  
 53. **Figure 43**  
 54. **Figure 44**  
 55. **Figure 45**  
 56. **Figure 46**  
 57. **Figure 47**  
 58. **Figure 48**  
 59. **Figure 49**  
 60. **Figure 50**  
 61. **Figure 51**  
 62. **Figure 52**  
 63. **Figure 53**  
 64. **Figure 54**  
 65. **Figure 55**  
 66. **Figure 56**  
 67. **Figure 57**  
 68. **Figure 58**  
 69. **Figure 59**  
 70. **Figure 60**  
 71. **Figure 61**  
 72. **Figure 62**  
 73. **Figure 63**  
 74. **Figure 64**  
 75. **Figure 65**  
 76. **Figure 66**  
 77. **Figure 67**  
 78. **Figure 68**  
 79. **Figure 69**  
 80. **Figure 70**  
 81. **Figure 71**  
 82. **Figure 72**  
 83. **Figure 73**  
 84. **Figure 74**  
 85. **Figure 75**  
 86. **Figure 76**  
 87. **Figure 77**  
 88. **Figure 78**  
 89. **Figure 79**  
 90. **Figure 80**  
 91. **Figure 81**  
 92. **Figure 82**  
 93. **Figure 83**  
 94. **Figure 84**  
 95. **Figure 85**  
 96. **Figure 86**  
 97. **Figure 87**  
 98. **Figure 88**  
 99. **Figure 89**  
 100. **Figure 90**  
 101. **Figure 91**  
 102. **Figure 92**  
 103. **Figure 93**  
 104. **Figure 94**  
 105. **Figure 95**  
 106. **Figure 96**  
 107. **Figure 97**  
 108. **Figure 98**  
 109. **Figure 99**  
 110. **Figure 100**  
 111. **Figure 101**  
 112. **Figure 102**  
 113. **Figure 103**  
 114. **Figure 104**  
 115. **Figure 105**  
 116. **Figure 106**  
 117. **Figure 107**  
 118. **Figure 108**  
 119. **Figure 109**  
 120. **Figure 110**  
 121. **Figure 111**  
 122. **Figure 112**  
 123. **Figure 113**  
 124. **Figure 114**  
 125. **Figure 115**  
 126. **Figure 116**  
 127. **Figure 117**  
 128. **Figure 118**  
 129. **Figure 119**  
 130. **Figure 120**  
 131. **Figure 121**  
 132. **Figure 122**  
 133. **Figure 123**  
 134. **Figure 124**  
 135. **Figure 125**  
 136. **Figure 126**  
 137. **Figure 127**  
 138. **Figure 128**  
 139. **Figure 129**  
 140. **Figure 130**  
 141. **Figure 131**  
 142. **Figure 132**  
 143. **Figure 133**  
 144. **Figure 134**  
 145. **Figure 135**  
 146. **Figure 136**  
 147. **Figure 137**  
 148. **Figure 138**  
 149. **Figure 139**  
 150. **Figure 140**  
 151. **Figure 141**  
 152. **Figure 142**  
 153. **Figure 143**  
 154. **Figure 144**  
 155. **Figure 145**  
 156. **Figure 146**  
 157. **Figure 147**  
 158. **Figure 148**  
 159. **Figure 149**  
 160. **Figure 150**  
 161. **Figure 151**  
 162. **Figure 152**  
 163. **Figure 153**  
 164. **Figure 154**  
 165. **Figure 155**  
 166. **Figure 156**  
 167. **Figure 157**  
 168. **Figure 158**  
 169. **Figure 159**  
 170. **Figure 160**  
 171. **Figure 161**  
 172. **Figure 162**  
 173. **Figure 163**  
 174. **Figure 164**  
 175. **Figure 165**  
 176. **Figure 166**  
 177. **Figure 167**  
 178. **Figure 168**  
 179. **Figure 169**  
 180. **Figure 170**  
 181. **Figure 171**  
 182. **Figure 172**  
 183. **Figure 173**  
 184. **Figure 174**  
 185. **Figure 175**  
 186. **Figure 176**  
 187. **Figure 177**  
 188. **Figure 178**  
 189. **Figure 179**  
 190. **Figure 180**  
 191. **Figure 181**  
 192. **Figure 182**  
 193. **Figure 183**  
 194. **Figure 184**  
 195. **Figure 185**  
 196. **Figure 186**  
 197. **Figure 187**  
 198. **Figure 188**  
 199. **Figure 189**  
 200. **Figure 190**  
 201. **Figure 191**  
 202. **Figure 192**  
 203. **Figure 193**  
 204. **Figure 194**  
 205. **Figure 195**  
 206. **Figure 196**  
 207. **Figure 197**  
 208. **Figure 198**  
 209. **Figure 199**  
 210. **Figure 200**  
 211. **Figure 201**  
 212. **Figure 202**  
 213. **Figure 203**  
 214. **Figure 204**  
 215. **Figure 205**  
 216. **Figure 206**  
 217. **Figure 207**  
 218